Royal Wound-X to Launch and Showcase New Cutting-Edge Technologies at SAWC 2024

HACKENSACK, NJ/ ACCESSWIRE / October 1, 2024 / Royal Wound-X, a division of Royal Biologics, is proud to announce that it will be showcasing two cutting-edge products at the 2024 Symposium on Advanced Wound Care (SAWC) Fall Conference in Las Vegas, Nevada.

The highlight of this year’s showcase includes the launch of Peak Powder Collagen Matrix, a next-generation collagen-based wound care solution designed to enhance healing in both surgical and non-surgical wounds. Composed of 100% bovine Type 1 collagen, Peak Powder optimizes the wound environment, supports tissue regeneration, and significantly speeds up the healing process.

Upon application, Peak Powder Collagen Matrix forms a gel-like barrier that creates an optimal moist environment for tissue regeneration. This low-pH environment promotes critical biological processes such as granulation tissue formation and epithelialization. Additionally, Peak Powder helps regulate enzymes like Matrix Metalloproteinase (MMP), enhancing fibroblast proliferation and angiogenesis. With broad-spectrum antimicrobial protection, Peak Powder combats common hospital-acquired pathogens such as S. aureus, E. coli, and C. albicans, reducing the risk of infection.

Peak Powder Collagen Matrix has versatile applications across numerous surgical fields, including Orthopedics, Podiatry, Spine, Plastic Surgery, and General Surgery. It is also highly effective in treating burns and ulcers. In-vitro testing shows that Peak Powder can reduce wound healing time by up to 50% while absorbing up to 30 times its weight in wound exudate, offering significant benefits for patients and healthcare providers alike.

In addition to Peak Powder, Royal Wound-X will also be introducing ElectroFiber 3D™, a bioengineered, electrospun synthetic polymer matrix designed to accelerate wound healing. Comprised of resorbable polymers such as polyglycolic acid (PGA) and poly lactide co-caprolactone (PLCL), ElectroFiber 3D™ provides a microporous scaffold that supports cellular migration and proliferation. ElectroFiber 3D™ helps reduce the wound pH from 7.4 to 5.9 within 78 hours, and further to 4.0 within two weeks, creating an ideal environment for tissue regeneration and infection control.

Approved as a 510(k) Medical Device, ElectroFiber 3D™ Wound Matrix is indicated for use in both partial and full-thickness wounds, as well as burns. The product offers rapid wound closure, with clinical studies showing a reduction in healing time to under eight weeks with only two or fewer applications required.

Salvatore Leo, CEO and founder of Royal Biologics, remarked, “Peak Powder and ElectroFiber 3D represent new and innovative technologies we are launching to expand our portfolio in wound care. These unique technologies combine natural healing properties with cutting-edge science to provide a faster, more effective healing solution for patients.”

About Royal Wound-X: Royal Wound-X, a division of Royal Biologics, is committed to advancing the field of wound care with innovative solutions that enhance healing and improve patient outcomes. Dedicated to a patient-first approach, Royal Wound-X develops a broad range of products designed to address diverse wound care needs and improve quality of life.

For more information on Royal Wound-X’s products and services, visit www.royalwx.com.

Media Contact:
Mary Jo Murino
Phone: 201.488.1549
Email: support@royalbiologics.com
Website: www.royalwx.com

Contact Information

Royal Support Team
Royal Support Team
support@royalbiologics.com
5182216932

SOURCE: Royal Wound-X

View the original press release on newswire.com.

Staff

Recent Posts

Red Light Holland Announces Increased Order from Costco Canada for Happy Caps 2kg “Mega Block” Mushroom Home Grow Kits

Toronto, Ontario--(Newsfile Corp. - October 1, 2024) - Red Light Holland Corp. (CSE: TRIP) (FSE:…

3 hours ago

Phio Pharmaceuticals Announces Upcoming Presentation at ASGCT’s 2024 Advancing Gene + Cell Therapies for Cancer Conference

Marlborough, Massachusetts--(Newsfile Corp. - October 1, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical…

3 hours ago

Laxxon Medical and Adare Pharma Solutions Announce Joint Cooperation for Production of cGMP 3D Printed Oral Dosage Forms in Europe and US

The cooperation between Laxxon and Adare enables the clinical and commercial production of advanced drug…

3 hours ago

Innovations in Physiotherapy: Exploring New Technologies and Techniques That Improve Patient Outcomes

DUBAI, UAE / ACCESSWIRE / October 1, 2024 / Patient outcomes are being revolutionized by…

3 hours ago

Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada

Once approved by Health Canada, Adzenys and Cotempla will be the only orally disintegrating, extended-release…

3 hours ago